Filtered By:
Nutrition: Vitamins
Countries: UK Health

This page shows you your search results in order of relevance. This is page number 2.

Order by Relevance | Date

Total 23 results found since Jan 2013.

Effectiveness and safety of 110 or 150 mg dabigatran versus vitamin K antagonists in non ‐valvular atrial fibrillation.
ConclusionIn real life D110 and D150 were at least as effective and safer than VKA.
Source: British Journal of Clinical Pharmacology - November 13, 2018 Category: Drugs & Pharmacology Authors: Patrick Blin, Caroline Dureau ‐Pournin, Yves Cottin, Jacques Bénichou, Patrick Mismetti, Abdelilah Abouelfath, Regis Lassalle, Cécile Droz, Nicholas Moore Tags: ORIGINAL ARTICLE Source Type: research

Energy Drinks Have Become Wildly Popular With Teens. Here ’s Why it’s a Public Health Concern
This article was originally published on Undark. Read the original article.
Source: TIME: Health - June 28, 2019 Category: Consumer Health News Authors: Sara Talpos / Undark Tags: Uncategorized Food & Drink onetime syndication Source Type: news

Reducing delays to administration of prothrombin complex concentrate in patients with vitamin K antagonist-related intracerebral haemorrhage.
Abstract BACKGROUND/AIMS: Four-factor prothrombin complex concentrate is the first-line treatment in vitamin K antagonist-related intracerebral haemorrhage. Early administration is associated with improved patient outcomes. A quality improvement project investigated delays in prothrombin complex concentrate administration in vitamin K antagonist-related intracerebral haemorrhage in order to reduce the time from computed tomography scan confirming intracerebral haemorrhage to prothrombin complex concentrate administration (scan-to-needle time). METHOD: Twenty patients were identified by retrospective audit ove...
Source: British Journal of Hospital Medicine - February 1, 2020 Category: Internal Medicine Authors: Marrinan E, Chen L, Werring D, Turner D Tags: Br J Hosp Med (Lond) Source Type: research

Causal inference and evidence-based recommendations in occupational health and safety research
In this issue of the Journal, a group of distinguished Nordic researchers, led by Anne Helene Garde and including four of our Associated Editors, present a discussion paper that originated from a workshop and provides detailed recommendations on night shift work (1). The recommendations are very clear: to protect workers ’ health, night shift schedules should have: (i) ≤3 consecutive night shifts; (ii) shift intervals of ≥11 hours; and (iii) ≤9 hours shift duration. For pregnant women, night work should be limited to one shift per week. The authors acknowledge that under circumstances allowing better possibi lities...
Source: Scandinavian Journal of Work, Environment and Health - October 2, 2020 Category: Occupational Health Tags: Editorial Source Type: research

Associations of Dietary Intakes of Vitamins B1 and B3 with Risk of Mortality from Cardiovascular Disease among Japanese Men and Women: the Japan Collaborative Cohort Study
CONCLUSIONS: Higher dietary intakes of vitamins B1 and B3 were inversely associated with mortality from ischemic heart disease and a higher dietary intake of vitamin B1 was inversely associated with a reduced risk of mortality from heart failure among Japanese men and women.PMID:35466893 | DOI:10.1017/S0007114522001209
Source: The British Journal of Nutrition - April 25, 2022 Category: Nutrition Authors: Chengyao Tang Ehab S Eshak Kokoro Shirai Akiko Tamakoshi Hiroyasu Iso Source Type: research

CO33 Methodological Challenges and Considerations for Decision Makers When Assessing within-Class Comparative Effectiveness and Cost-Effectiveness: The Case of Non-Vitamin K Antagonist Oral Anticoagulants
The United Kingdom National Institute of Health Care Excellence (NICE) published a draft clinical guideline for consultation on anticoagulation therapy for stroke prevention in individuals with atrial fibrillation in September 2020 that addressed which non-vitamin K antagonist oral anticoagulant (NOAC) therapy (apixaban, dabigatran, rivaroxaban, edoxaban) is most clinically and cost-effective. We aimed to elucidate methodological considerations and challenges involved in evaluating the comparative effectiveness and cost-effectiveness of within-class treatments for the  purpose of decision making by a reimbursement authority.
Source: Value in Health - June 26, 2022 Category: International Medicine & Public Health Authors: A Briggs, A Howarth, S Davies, J Schneider, G Spentzouris, F Mughal, A Fuat, M Fay Source Type: research